Figure 3.
HSC phenotype is mitigated in Thpofl/fl;AlbCre+/− knockout mice. (A-B) PB platelet (Plt) counts (A) and BM HSC number (per femur) (B) in Thpo+/+, Thpo−/−, Thpofl/fl;AlbCre−/−Thpofl/fl;AlbCre+/−, and mice (n > 5). (C) Representative flow cytometric plot of cell cycle analysis and quantification of percentage of HSCs in the G0 phase of Thpo+/+, Thpofl/fl;AlbCre+/−, and Thpo−/− mice (n > 5). (D) Representative flow cytometric plot and quantification (mean fluorescence intensity [MFI] and percentage of positively gated cells) of Annexin V staining in Thpo+/+, Thpofl/fl;AlbCre+/−, and Thpo−/− HSCs (n = 4). (E) MFI of FSC parameter in Thpo+/+, Thpofl/fl;AlbCre+/−, and Thpo−/− HSCs (n = 4). (F) Thpo concentration in blood plasma of Thpo+/+, Thpofl/fl;AlbCre+/−, and Thpo−/− mice (n > 5). *P < .05, **P < .01, Tukey test (A-B,D-F), Fisher’s least significant difference test (C).